Akers Biosciences Inc (AKR) Earns “Corporate” Rating from FinnCap
Akers Biosciences Inc (LON:AKR)‘s stock had its “corporate” rating reiterated by research analysts at FinnCap in a report issued on Thursday.
Shares of Akers Biosciences (AKR) remained flat at GBX 72.50 on Thursday. 287 shares of the company were exchanged. The stock’s market capitalization is GBX 6.45 million. The company has a 50 day moving average price of GBX 87.16 and a 200-day moving average price of GBX 108.43. Akers Biosciences has a 12 month low of GBX 75.00 and a 12 month high of GBX 255.00.
COPYRIGHT VIOLATION NOTICE: “Akers Biosciences Inc (AKR) Earns “Corporate” Rating from FinnCap” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/08/27/akers-biosciences-inc-akr-earns-corporate-rating-from-finncap.html.
About Akers Biosciences
Akers Biosciences, Inc develops, manufactures and supplies point-of-care screening and testing products designed to bring health-related information to the patient or clinician. The Company’s product offerings and pipeline products focus on delivering diagnostic assistance in a range of healthcare fields/specialties, including cardiology/emergency medicine, metabolism/nutrition, diabetes, respiratory diseases and infectious diseases detection, as well as for on and off-the-job alcohol safety initiatives.
Receive News & Ratings for Akers Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akers Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.